CN103012387B - 伊潘立酮的制备方法 - Google Patents
伊潘立酮的制备方法 Download PDFInfo
- Publication number
- CN103012387B CN103012387B CN201210573439.4A CN201210573439A CN103012387B CN 103012387 B CN103012387 B CN 103012387B CN 201210573439 A CN201210573439 A CN 201210573439A CN 103012387 B CN103012387 B CN 103012387B
- Authority
- CN
- China
- Prior art keywords
- fluoro
- piperidyl
- benzoisoxazole
- zomaril
- hydroxypropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960003162 iloperidone Drugs 0.000 title claims abstract description 26
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- -1 6-[1-(3-hydroxypropyl)-4-piperidyl]-1,2-benzoisoxazole Chemical compound 0.000 claims abstract description 16
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 14
- FVHKXXNNJGZOBO-UHFFFAOYSA-N C(C)C(=O)CC.OC1=C(C=CC=C1)OC Chemical compound C(C)C(=O)CC.OC1=C(C=CC=C1)OC FVHKXXNNJGZOBO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000001475 halogen functional group Chemical group 0.000 claims abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229940058344 antitrematodals organophosphorous compound Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 150000002903 organophosphorus compounds Chemical class 0.000 claims description 8
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000006751 Mitsunobu reaction Methods 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 3
- UQSJMGQSZNHTHX-UHFFFAOYSA-N 6-piperidin-4-yl-1,2-benzoxazole Chemical compound C1CNCCC1C1=CC=C(C=NO2)C2=C1 UQSJMGQSZNHTHX-UHFFFAOYSA-N 0.000 claims description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 claims description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 3
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 claims description 3
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 150000005524 benzylchlorides Chemical class 0.000 claims description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 235000007715 potassium iodide Nutrition 0.000 claims description 2
- 229960004839 potassium iodide Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 5
- 238000004821 distillation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 3
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开的伊潘立酮的制备方法,包括如下步骤:6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与卤代丙醇发生N-烷基化反应,制得6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑,再与4-羟基-3-甲氧基苯乙酮发生Mitsunobu反应,得到4-[3-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]丙氧基]-3-甲氧基苯乙酮,即伊潘立酮。采用本发明制备伊潘立酮反应条件温和、反应时间短、收率高,且产品质量稳定、纯度高。
Description
技术领域
本发明涉及抗精神病和镇痛药物伊潘立酮的制备方法。
背景技术
伊潘立酮,化学名为4-[3-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]丙氧基]-3-甲氧基苯乙酮,是一种新型非典型抗精神病药,临床用于治疗成人精神分裂症,具有同时拮抗5-HT2受体和D2受体的双重作用,对前者的亲和力较对后者高一个数量级;对肾上腺素α1受体亦具极高亲和力,但对α2、5-HT1A、σ和D1受体的亲和力则低很多。表明其为一潜在的具有较少副作用的广谱抗精神病药物。
在美国专利US5364866、USRE39198和欧洲专利EP402644B1中,公开了伊潘立酮的制备方法,该方法通过6-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐和4-(3-氯丙氧基)-3-甲氧基苯乙酮发生N-烷基化反应,得到伊潘立酮。PCT专利WO2010031497也有报道通过6-氟-3-(4-哌啶基)-1,2-苯并异噁唑和1-溴-3-氯丙烷反应,合成6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑,再与4-羟基-3-甲氧基苯乙酮进行偶联反应得到4-[3-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]丙氧基]-3-甲氧基苯乙酮,即伊潘立酮。但以上方法采用了1-溴-3-氯丙烷为原料,反应过程中有副产物生成,导致收率低、产品后处理及纯化较为困难,而且产品纯度差。
因此,鉴于伊潘立酮良好的药用前景,需要开发一种制备伊潘立酮的新方法。
发明内容
本发明的目的是提供一种收率良好、成本较低、产品纯度高的制备伊潘立酮的方法。
本发明的伊潘立酮的制备方法,依次包括如下步骤:
第一步,在非质子性极性溶剂、碱性试剂和碘盐存在下,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与卤代丙醇在50~90℃下反应18~24 h,反应液经过滤、浓缩、水洗和重结晶,得到6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与卤代丙醇的摩尔比为1:1.1~1.5,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与碱性试剂的摩尔比为1:1~2,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与碘盐的摩尔比为1:0.1~0.2,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与非质子性极性溶剂的重量比为1:5~10;
第二步,在N2保护下,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁与4-羟基-3-甲氧基苯乙酮在Mitsunobu反应条件下于无水醚类溶剂中,0~25℃反应0.5~1 h,反应液经柱层析分离得到伊潘立酮,所说的Mitsunobu反应条件是偶氮试剂和有机磷化合物存在,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与4-羟基-3-甲氧基苯乙酮的摩尔比为1:1.1~1.5,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与偶氮试剂的摩尔比为1:1.5~2,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与有机磷化合物的摩尔比为1:1.5~2,偶氮试剂与有机磷化合物的摩尔比为1:1,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与所用无水醚类溶剂的重量比为1:8~16。
具体合成路线如下:
本发明制备方法中:第一步反应中所用的非质子性极性溶剂为N,N-二甲基甲酰胺、丙酮或乙腈,所用的碱性试剂为碳酸钾、碳酸钠、碳酸氢钠、氢氧化钾或氢氧化钠,所用的碘盐为碘化钾或碘化钠,所用的卤代丙醇为3-氯丙醇或3-溴丙醇。
第二步反应中所用的无水醚类溶剂为无水乙醚、无水四氢呋喃或无水2-甲基四氢呋喃,所用的偶氮试剂为偶氮二甲酸二乙酯、偶氮二甲酸二异丙酯、偶氮二甲酸二对硝基苄酯、偶氮二甲酸二对氯苄酯或偶氮二甲酸二苄酯;所用的有机磷化合物为三苯基膦、三丁基膦或三环己基膦。
采用本发明方法的有益效果在于:
1.反应过程副产物少,后处理及纯化较为简单,反应成本低;
2.收率高,反应条件温和,反应时间短;
3.制得的伊潘立酮色泽好,纯度高。
具体实施方式
以下结合实施例对本发明作进一步详细描述。
实施例1:
第一步:将6-氟-3-(4-哌啶基)-1,2-苯并异噁唑(1.50 g,6.81 mmol), 3-氯丙醇(0.72 g,7.49 mmol), K2CO3 (0.96 g,6.81 mmol),KI (0.23 g,1.36 mmol)加入装有乙腈(9.5 mL,7.50 g)的三口烧瓶中,81℃反应20 h。反应液过滤、浓缩,浓缩液溶于15 mL二氯甲烷,然后水洗(15 mL×2),有机层减压蒸馏除去二氯甲烷,所得固体用乙醇/水重结晶,得黄色固体6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(1.43g,收率75.4%);
第二步:在N2保护下,将4-羟基-3-甲氧基苯乙酮(0.23 g,1.40 mmol),6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(0.26 g,0.93 mmol)和三苯基膦 (0.49 g,1.87 mmol)加入装有无水四氢呋喃(4.7 mL,4.16 g)的三口瓶中,缓慢滴加偶氮二甲酸二异丙酯(0.38 g,1.87 mmol),25℃下反应0.5 h。反应液经柱层析分离,得白色固体伊潘立酮(0.35 g,收率87.5%)。
实施例2:
第一步:将6-氟-3-(4-哌啶基)-1,2-苯并异噁唑(1.00 g,4.54 mmol), 3-氯丙醇(0.56 g,5.90 mmol), Na2CO3 (0.48 g,4.54 mmol),NaI (0.14 g,0.91 mmol)加入装有丙酮(8.0 mL,6.28 g)的三口烧瓶中,56℃反应24 h。反应液过滤、浓缩,浓缩液溶于15 mL二氯甲烷,然后水洗(15 mL×2),有机层减压蒸馏除去二氯甲烷,所得固体用乙醇/水重结晶,得黄色固体6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(0.97g,收率76.4%);
第二步:在N2保护下,将4-羟基-3-甲氧基苯乙酮(0.75 g,4.52 mmol),6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(0.90 g,3.23 mmol)和三环己基膦 (1.63 g,5.81 mmol)加入装有无水四氢呋喃(14.2 mL,12.6 g)的三口瓶中,缓慢滴加偶氮二甲酸二对氯苄酯 (2.13 g,5.81 mmol),20℃下反应0.5h。反应液经柱层析分离,得白色固体伊潘立酮(1.18 g ,收率85.5%)。
实施例3:
第一步:将6-氟-3-(4-哌啶基)-1,2-苯并异噁唑(1.00 g,4.54 mmol), 3-溴丙醇(0.69 g,4.99 mmol), NaHCO3 (0.76 g,9.08 mmol),NaI (0.07 g,0.45 mmol)加入装有DMF(8.5 mL,8.03 g)的三口烧瓶中,90℃反应24 h。反应液过滤、浓缩,浓缩液溶于15 mL二氯甲烷,然后水洗(15 mL×2),有机层减压蒸馏除去二氯甲烷,所得固体用乙醇/水重结晶,得黄色固体6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(0.99 g,收率78.6%);
第二步:在N2保护下,将4-羟基-3-甲氧基苯乙酮(0.70 g, 4.20 mmol),6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(0.90 g,3.23 mmol)和三丁基膦 (1.05 g,5.17 mmol)加入装有无水2-甲基四氢呋喃(10.5 mL,9.00 g)的三口瓶中,缓慢滴加偶氮二甲酸二苄酯 (1.54g,5.17 mmol),15℃下反应1h。反应液经柱层析分离,得白色固体伊潘立酮(1.16 g ,收率84.1%)。
实施例4:
第一步:将6-氟-3-(4-哌啶基)-1,2-苯并异噁唑(1.00 g,4.54 mmol), 3-氯丙醇(0.64 g,6.81 mmol),KOH (0.38 g,6.81 mmol),KI (0.11 g,0.68 mmol)加入装有DMF(10.6 mL,10.00 g)的三口烧瓶中,90℃反应18 h。反应液过滤、浓缩,浓缩液溶于15 mL二氯甲烷,然后水洗(15 mL×2),有机层减压蒸馏除去二氯甲烷,所得固体用乙醇/水重结晶,得黄色固体6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(1.01g,收率80.2%);
第二步:在N2保护下,将4-羟基-3-甲氧基苯乙酮(0.59 g,3.55 mmol),6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑(0.90 g,3.23 mmol)和三苯基膦 (1.27 g,4.85 mmol)加入装有无水乙醚(10.1 mL,7.2 g)的三口瓶中,缓慢滴加偶氮二甲酸二乙酯 (0.84 g,4.85 mmol),0℃下反应1 h。柱层析分离,得白色固体伊潘立酮(1.11 g,收率80.4%)。
Claims (5)
1.伊潘立酮的制备方法,包括如下步骤:
第一步,在非质子性极性溶剂、碱性试剂和碘盐存在下,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与卤代丙醇在50~90℃下反应18~24 h,反应液经过滤、浓缩、水洗和重结晶,得到6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与卤代丙醇的摩尔比为1:1.1~1.5,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与碱性试剂的摩尔比为1:1~2,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与碘盐的摩尔比为1:0.1~0.2,6-氟-3-(4-哌啶基)-1,2-苯并异噁唑与非质子性极性溶剂的重量比为1:5~10,所用的卤代丙醇为3-氯丙醇或3-溴丙醇;
第二步,在N2保护下,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁与4-羟基-3-甲氧基苯乙酮在Mitsunobu反应条件下于无水醚类溶剂中,0~25℃反应0.5~1 h,反应液经柱层析分离得到伊潘立酮,所说的Mitsunobu反应条件是偶氮试剂和有机磷化合物存在,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与4-羟基-3-甲氧基苯乙酮的摩尔比为1:1.1~1.5,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与偶氮试剂的摩尔比为1:1.5~2,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与有机磷化合物的摩尔比为1:1.5~2,偶氮试剂与有机磷化合物的摩尔比为1:1,6-氟-3-[1-(3-羟丙基)-4-哌啶基]-1,2-苯并异噁唑与所用无水醚类溶剂的重量比为1:8~16,所用的偶氮试剂为偶氮二甲酸二乙酯、偶氮二甲酸二异丙酯、偶氮二甲酸二对硝基苄酯、偶氮二甲酸二对氯苄酯或偶氮二甲酸二苄酯,所用的有机磷化合物为三苯基膦、三丁基膦或三环己基膦。
2.按权利要求1所述的伊潘立酮的制备方法,其特征在于第一步反应中所用的非质子性极性溶剂为N,N-二甲基甲酰胺、丙酮或乙腈。
3.按权利要求1所述的伊潘立酮的制备方法,其特征在于第一步反应中所用的碱性试剂为碳酸钾、碳酸钠、碳酸氢钠、氢氧化钾或氢氧化钠。
4.按权利要求1所述的伊潘立酮的制备方法,其特征在于第一步反应中所用的碘盐为碘化钾或碘化钠。
5.按权利要求1所述的伊潘立酮的制备方法,其特征在于第二步反应中所用的无水醚类溶剂为无水乙醚、无水四氢呋喃或无水2-甲基四氢呋喃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210573439.4A CN103012387B (zh) | 2012-12-26 | 2012-12-26 | 伊潘立酮的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210573439.4A CN103012387B (zh) | 2012-12-26 | 2012-12-26 | 伊潘立酮的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103012387A CN103012387A (zh) | 2013-04-03 |
CN103012387B true CN103012387B (zh) | 2015-08-12 |
Family
ID=47961541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210573439.4A Expired - Fee Related CN103012387B (zh) | 2012-12-26 | 2012-12-26 | 伊潘立酮的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103012387B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114014825B (zh) * | 2021-11-10 | 2023-06-02 | 河南师范大学 | 一种组胺h3受体拮抗剂替洛利生的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
CN1136275A (zh) * | 1993-10-28 | 1996-11-20 | 赫彻斯特-柔斯尔药物公司 | 芳杂环基哌啶类、吡咯烷类及哌嗪类及其作为抗精神病药和止痛药的用途 |
CN102212063A (zh) * | 2011-05-10 | 2011-10-12 | 北京美迪康信医药科技有限公司 | 一种伊潘立酮的制备方法 |
-
2012
- 2012-12-26 CN CN201210573439.4A patent/CN103012387B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
CN1136275A (zh) * | 1993-10-28 | 1996-11-20 | 赫彻斯特-柔斯尔药物公司 | 芳杂环基哌啶类、吡咯烷类及哌嗪类及其作为抗精神病药和止痛药的用途 |
CN102212063A (zh) * | 2011-05-10 | 2011-10-12 | 北京美迪康信医药科技有限公司 | 一种伊潘立酮的制备方法 |
Non-Patent Citations (1)
Title |
---|
利用Mitsunobu反应合成芳基吡啶烷基醚;唐子龙;《精细化工中间体》;20060630;第36卷(第3期);第23-27页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103012387A (zh) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101653064B1 (ko) | 가도부트롤의 제조방법 | |
CN106749027B (zh) | 一种盐酸右美托咪定中间体的合成工艺 | |
CN101962379B (zh) | 一种磺酰基异喹啉衍生物的精制方法 | |
CN103570609A (zh) | 一种2,3-二氯吡啶的制备方法 | |
CN103435575A (zh) | 1-( 3-( 3-( 4-氯苯基)丙氧基)丙基)哌啶盐酸盐的制备方法 | |
CN102617434B (zh) | 一锅法制备维达列汀 | |
CN102617542A (zh) | 一种奥美沙坦中间体的制备方法及纯化方法 | |
CN103012387B (zh) | 伊潘立酮的制备方法 | |
US10399992B2 (en) | Process for preparing AD-35 | |
CN106520892B (zh) | 7-氨基-3-乙烯基头孢烷酸的制备方法 | |
CN106279175A (zh) | 一种厄他培南单钠盐的制备方法 | |
US20140200355A1 (en) | Method for Preparing Optically Pure (-)-Clausenamide Compound | |
CN103739604A (zh) | 一种适合工业放大生产普拉曲沙的制备方法 | |
CN103304567B (zh) | 一种替卡格雷的制备方法 | |
CN105358529A (zh) | 一种合成阿哌沙班重要中间体的新方法 | |
CN103965059B (zh) | 一种制备(1r,2s)‑2‑(3,4‑二氟苯基)环丙胺的方法 | |
CN108069956B (zh) | 1-氮杂双环[2,2,2]辛-4-基苯基酮化合物及其制备方法和应用 | |
CN113773322B (zh) | 一种Filgotinib的制备方法 | |
US20200062720A1 (en) | Novel preparation method for anti-gout drug lesinurad, and key intermediate thereof | |
CN105440025B (zh) | 一种制备卡格列净及其中间体的方法及所述中间体 | |
KR101127618B1 (ko) | 4-[(4-클로로페닐)(2-피리딜)메톡시]피페리딘의 제조방법 | |
CN103524530A (zh) | 普拉格雷氢溴酸盐及其制备方法 | |
CN103554105A (zh) | 一种9-羟基利培酮的纯化方法 | |
KR101694262B1 (ko) | 실로도신의 결정형의 제조방법 | |
CN107033090A (zh) | 一种1,2,3,4‑四氢噌啉的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150812 Termination date: 20181226 |
|
CF01 | Termination of patent right due to non-payment of annual fee |